You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 73 No. 2, February 1956 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (38)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Treatment of Keloids with Topical Injections of Hydrocortisone Acetate

G. ASBOE-HANSEN, M.D.; H. BRODTHAGEN, M.D.; LIS ZACHARIAE, M.D.

AMA Arch Derm. 1956;73(2):162-165.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Fresh keloids consist of dense bundles of collagenous fibrils and an ample mucinous ground substance with a high content of mucopolysaccharides. Mast cells and fibroblasts are present in large numbers. Keloids of longer standing are less cellular, with fibril bundles predominating, whereas the ground substance is less ample.

Since cortisone and hydrocortisone are known to influence the chemistry and morphology of connective tissue cells and to inhibit their production of intercellular substance,1 it is reasonable to expect that keloids would be susceptible to treatment with adrenocortical steroids.

In patients with Cushing's syndrome wounds and scars are apt to become distended. This is also observed in patients on systemic treatment with corticotropin (ACTH) and cortisone. In such patients softening of keloids has been noted as well.* This effect is, however, too slight and undependable to acquire any therapeutic importance. A more marked effect must be expected . . . [Full Text PDF of this Article]


Author Affiliations

Copenhagen

From The Finsen Institute, Department of Dermatology (Chief: Professor P. V. Marcussen, M.D.) and The Orthopedic Hospital, Department I (Chief: Arne Bertelsen, M.D.).


Footnotes

Submitted for publication April 26, 1955.

This work aided by grants from Eli Lilly & Company, Indianapolis, and King Christian X Foundation.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1956 American Medical Association. All Rights Reserved.